OVR110 antibody compositions and methods of use
Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
1. An isolated monoclonal antibody or antigen binding fragment thereof, wherein the isolated monoclonal antibody or antigen binding fragment thereof competes with a reference antibody for binding to the epitope on Ovr110 bound by the reference antibody, said reference antibody or antigen binding fragment thereof comprising:
(a) a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 12, 22, 32 and 42; and
(b) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 17, 27, 37 and 47.
2. The antibody of claim 1 , wherein the isolated monoclonal antibody is a human, humanized or chimeric antibody.
3. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 which inhibits Ovr110 function.
4. The isolated monoclonal antibody or antigen binding fragment thereof of claim 3 , wherein Ovr110 function is suppression of immune response against Ovr110-expressing cells.
5. The isolated monoclonal antibody or antigen binding fragment thereof of claim 4 , wherein Ovr110 suppression of immune response is via lymphocyte regulation.
6. The isolated monoclonal antibody or antigen binding fragment thereof of claim 5 , wherein lymphocyte regulation is selected from the group consisting of T cell activation, B cell activation, NK cell activation, T cell proliferation, B cell proliferation, NK cell proliferation, T cell tumor infiltration, B cell tumor infiltration and NK cell tumor infiltration.
7. A composition comprising the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.
8. An immunoconjugate comprising the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 conjugated to a cytotoxic agent.
9. A composition comprising the immunoconjugate of claim 8 , and a pharmaceutically acceptable carrier.
10. A bispecific molecule comprising the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 , linked to a second functional moiety having a different binding specificity than said antibody or antigen binding fragment thereof.
11. A composition comprising the bispecific molecule of claim 10 , and a pharmaceutically acceptable carrier.
12. The isolated monoclonal antibody or antigen binding fragment thereof of claim 1 which is labeled.
13. The isolated monoclonal antibody or antigen binding fragment of claim 12 wherein the label is selected from the group comprising radioisotope, fluorescent, and enzymatic labels.
14. A kit for detecting Ovr110 expression comprising the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 .
15. The kit of claim 14 further comprising a container and a composition contained therein comprising the isolated monoclonal antibody of antigen binding fragment thereof of claim 1 .
16. The kit of claim 15 further comprising a label or package insert on or associated with the container.
17. The kit of claim 14 wherein the kit is an ELISA.